Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Inks Target Validation, Data-Sharing Deal with Bristol-Myers Squibb

Premium

Tekmira Pharmaceuticals said this week that it has signed a four-year target-validation deal with drug maker Bristol-Myers Squibb.

Under the deal, Bristol-Myers Squibb will use siRNAs formulated with Tekmira's stable nucleic acid-lipid particle-based delivery technology to "validate the function of certain cellular targets," the companies said.

Notably, Bristol-Myers Squibb will conduct the preclinical validation work, but has agreed to share the data it generates with Tekmira, which is free to use the data to develop RNAi-based drugs against the targets.

Tekmira will receive $3 million upfront, and is responsible for providing "a pre-determined number of the SNALP batches over the four-year agreement," the firms said. "Bristol-Myers Squibb will have a first right to negotiate a licensing agreement on certain RNAi products developed by Tekmira that evolve from gene targets" it validates.

Additional terms were not disclosed.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.